Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

tion of additional clinical trials and the timing thereof and the use of Kosan's financial resources. Words such as "will," "expect," "believe," "may," "intend," "plan," "potential" and similar expressions are intended to identify forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Kosan's current expectations. Forward-looking statements involve risks and uncertainties. Kosan's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the acquisition of Kosan by Bristol-Myers Squibb may not be consummated as the transaction is subject to certain closing conditions, risks related to the uncertain progress and results of Kosan's preclinical and clinical testing, including the risks that studies and trials may not demonstrate safety and efficacy sufficient to initiate clinical trials on the timing currently anticipated, or at all, continue clinical development, obtain the requisite regulatory approvals or result in a marketable product; the conduct of clinical trials; manufacturing; regulatory approval requirements and process; the effort and expense necessary for further development of Kosan's product candidates, including the costs of bortezomib; intellectual property matters, including Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan' dependence on it license with Bristol-Myers Squibb to develop its epothilone products in order for Kosan to receive milestones or royalties, Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and other
'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the Morgan Stanley Global Healthcare Conference in ... Tuesday September 9, 2014 , Presentation time: 5:15 p.m. ... archive of this presentation will be available at http://ir.avanir.com ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing ...
(Date:9/2/2014)... 2014  Edison Nation Medical, the premier healthcare ... American Association for Respiratory Care ( AARC ), ... Edison Nation Medical, which brings 12+ years experience ... their innovation ideas, will work with AARC to ... 50,000 respiratory therapists in bringing their product innovation ...
(Date:9/2/2014)... Today, Analysts Review released its ... ), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR ), ... (NYSE: SNY ) and GlaxoSmithKline plc (NYSE: ... publication. To reserve complementary membership, limited openings are available ... Reports ,WellPoint Inc. (WellPoint) posted on the Events and ...
Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... Operators in the Community Services industry ... arranging care and counsel for those in need. In ... to derive $39.4 billion in revenue, which includes a ... the five years through 2014-15, the subdivision is forecast ... growth of 4.1% in 2014-15. , As the population ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. ... with weight loss by blocking a certain nerve linked to ... among obese patients. Using electric impulses to block the ... hoped to suppress feelings of hunger. And, they did, just ... safely blocks the nerve that connects the brain to the ...
(Date:9/2/2014)... LEBANON, NH Doctors trained in locations with less ... better at making clinical decisions that spare patients unnecessary ... in JAMA Internal Medicine . , "Growing concern ... spurred interest in assessing physicians, ability to avoid the ... of the VA Outcomes Group and The Dartmouth Institute ...
(Date:9/2/2014)... GA (PRWEB) September 02, 2014 Last year, ... new level with the launch of a luxurious line of ... announce that the SEA ISLAND COTTON Socks are joining the ... level, giving more people the comfort of natural cotton fibers. ... Socks, they are surprised to find socks as soft as ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2
... ETT assessment is used to diagnose diseases, ... achalasia. These studies are commonly performed in ... the use of ionizing radiation and catheters, ... Recently, several types of assessments were performed ...
... question whether a common European position on advance directives, ... was discussed at a recent workshop organised by the ... allows people to specify how they would like their ... living will is supposed to determine what medical treatment ...
... Impact of McCain, Obama,Proposals, WASHINGTON, Oct. 31 ... and costs are continuing to skyrocket --,making health care ... United States., A detailed analysis of each candidate,s ... government is included in the Guide to,Healthcare: The 2008 ...
... Wolters Kluwer, a,market leading global information services and ... of Robert Becker to the,position of President and ... Becker is currently CEO of Wolters Kluwer Law ... CEO of Wolters Kluwer Law &,Business (U.S.)., ...
... National Plan to Make LTC Affordable, NEW YORK, ... care (LTC) financing stands to undermine our family care,giving ... up with a,solution, a panel of speakers said today ... forum featured national and state policy experts discussing,different potential ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... Arcapita Inc. and Health Care REIT (HCN), under,which HCN ... owning 29 senior,housing properties managed by Sunrise, has been ... on Sunrise,s 10% interest in the,venture. Sunrise will continue ...
Cached Medicine News:Health News:A biomagnetic diagnostic technique to evaluate esophageal transit time 2Health News:Europe seeks consensus over 'living wills' 2Health News:Europe seeks consensus over 'living wills' 3Health News:Candidates' Proposals to Address Health Care Cost, Coverage and Quality Come at Major Costs 2Health News:Candidates' Proposals to Address Health Care Cost, Coverage and Quality Come at Major Costs 3Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 2Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 3Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 4Health News:State and National Leaders Call for Long-term Care Financing Reform 2Health News:State and National Leaders Call for Long-term Care Financing Reform 3Health News:State and National Leaders Call for Long-term Care Financing Reform 4Health News:Sunrise Provides Update on HCN Transaction 2Health News:Sunrise Provides Update on HCN Transaction 3Health News:Sunrise Provides Update on HCN Transaction 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: